BrainXell provides iPSC-derived human neurons to the pharmaceutical industry and other research organizations for CNS drug discovery and development. Utilizing proprietary technology developed over the last two decades by Professor Su-Chun Zhang at the University of Wisconsin-Madison, we generate high-purity, subtype-specific neurons that rapidly mature. Multiple neuron subtypes relevant to a range of disorders are available. Neurons and glia can be made in custom batches from 50 million to 10 billion neurons from iPSC or ESC lines selected by the customer. Additionally, iPSC lines can be generated from fibroblasts through mRNA reprogramming.